semaj83/ctmatch_classification huggingface dataset:
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Diarrhea Male or female subjects (equal numbers of males and females) Volunteers aged of at least 18 years but not older than 55 years Subjects will have a Body Mass Index (BMI) within protocol-specified parameters Non or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking for at least 12 months before day 1 of this study Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations Has signed and dated the informed consent document, indicating that the subject has been informed of all pertinent aspects of the study Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures  Seated pulse rate and blood pressure within protocol-specified parameters Relationship to persons involved directly with the conduct of the study (i.e., principal investigator; sub-investigators; study coordinators; other study personnel; employees or contractors of the sponsor or Johnson & Johnson subsidiaries; and the families of each) Females who are pregnant or are lactating Females of childbearing potential or males with a female partner of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study History of significant hypersensitivity to racecadotril or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs Use of certain drugs/medications within protocol-specified timeframes Medical history or condition that may, per protocol or in the opinion of the investigator, adversely affect the safety of the study subject or compromise study results
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Type 1 Diabetes Healthy adults (aged 18-55) with >5 years disease duration On intensive insulin therapy (CSII or multiple daily injections) HbA1C<8.0% Ability to give written informed consent to participate in the study BMI between 20-29  History of significant cardiac, hepatic, renal or neurological disease Significant head injury, epilepsy or hypoglycaemia-induced seizures Pregnancy Breast feeding mothers Participants on thiazide diuretics Participants on other potassium channel openers (nicorandil, minoxidil) Participants on medications with vasodilatory properties such as methyldopa, reserpine, theophyllines and nitrites Participants on hydantoins (fosphenytoin, phenytoin) Significant anaemia Hb<11.0 and Hct<33% If they have donated blood in the last 30 days
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Diarrhoea Lymphocytic Colitis Collagenous Colitis Patients with chronic non-bloody diarrhea for at least one month  Patients who decline to participate Unable to give informed consent
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Appendicitis Perforated Gastroduodenal Ulcer Small Bowel Obstruction patient older > 18 years Patient indicated for emergent surgery for: acute appendicitis / perforated gastric or duodenal ulcer / small bowel obstruction The patient can understand the aim of the study and sign informed consent (including language barriers) The diagnose is confirmed intraoperatively  Refused the participation in the study and uninsured self-payers Patients with known allergy to the substance administered during the study or chronic medication contraindicated with study drug Pregnant or breastfeeding women Use of antibiotics in the last 2 weeks Known serious illness (heart failure, renal failure, liver failure, CNS disorders) Signs of infectious mononucleosis and risk of infectious endocarditis
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 1.0-999.0,  Vibrio Cholerae Cholera Male or female adults aged 18 years and above; and children aged 1 -17 years who is available for follow-up visits and specimen collection The subject should be able to continue in the study for the next 4 weeks The subject (or parent/guardian) should be willing to provide 3 blood samples 2. For females of reproductive age, non-pregnant (as determined by urine pregnancy test). 3. Written informed consent obtained from the subjects or their parents/guardians, and written assent obtained from children aged 12 years. 4. Healthy subjects as determined by Medical history Physical examination Clinical judgment of the investigator  Ongoing chronic recurring illness which may cause systemic symptoms as judged by the investigating physician. 2. Ongoing acute illness. 3. For females of reproductive age: Pregnancy (or females planning to become pregnant during the study period; as determined by verbal screening) 4. Immunocompromising condition or on chronic systemic steroid therapy 5. Diarrhea (3 or more loose/more watery stools within a 24-hour period) within 6 weeks prior to enrollment 6. Intake of any anti-diarrhea medicine in the past week 7. Abdominal pain or cramps, loss of appetite, nausea, or vomiting in the past 24 hours 8. Temperature ≥38ºC (oral or axillary) warrants deferral of the vaccination pending recovery of the subject 9. Previous hypersensitivity to formaldehyde. 10. Receipt of immunoglobulin or any blood product during the past 3 months 11. Receipt of oral cholera vaccine in the past three years 12. Any potential subject currently participating or who will participate within the next six months in another clinical trial 13. Positive screening urine pregnancy test for females greater than 12 years of age
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Osteoarthritis Post-traumatic Arthritis Gout Pseudo-gout Male or female subjects, aged at least 21 years Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained Subjects, who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups Subject has non-inflammatory degenerative joint disease (NIDJD), including: osteoarthritis, posttraumatic arthritis, avascular necrosis and chondrocalcinosis Subject has a functional stable knee Subject, in the opinion of the Investigator, is suitable for either a single or bicompartmental knee replacement Subject meets the following selected radiographic parameters X-ray evaluation confirms the presence of NIDJD Disease location: 1 to 2 compartments, maximum. Disease can be present in the patellofemoral compartment, the medial tibiofemoral compartment, lateral tibiofemoral compartments alone or in any two compartments Disease severity: Kellgren and Lawrence44 Grade II or greater for all compartments replaced  Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation Women who are pregnant Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes Subjects who have participated in a clinical investigation with an investigational product in the last 3 months Subjects who are currently involved in any injury litigation claims Multiple joint involvement that will compromise rehabilitation (for example: advanced hip, ankle or spine disease) Known to be a prisoner, mentally incompetent, an alcohol / drug abuser, involved in medical-legal case or worker's compensation Previous knee arthroplasty (any type) in any one of the three compartments of the knee Requires more than a lateral soft tissue release or an anterior cruciate ligament reconstruction Uncorrectable anatomical tibio-femoral angle
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diarrhea Fever Vomiting Abdominal Pain Patients with culture-positive stool sample with Campylobacter concisus Diarrheic patients ≥ 18 years symptoms of diarrhea defined as three or more watery stools per day or two watery stools per day + at least one of the following symptoms: abdominal pain, nausea, vomiting or fever Diarrheic symptoms for a minimum of 24 hours before enrollment Diarrheic symptoms for a maximum of 21 days before enrollment Informed oral and signed written consent, with documentation that all relevant information about the study is given to the patient The patient must be willing and able to participate in the trial  Hypersensitivity to azithromycin, erythromycin, macrolide or other ketolide-antibiotics Pregnancy or breastfeeding (if relevant) Culture positive stool sample with a Co-pathogen Treatment with other antibiotics (in any stage 21 days before the first stool sample) Patients with severe liver disease Patients with severe renal impairment (GFR <10 ml / min) Patients with congenital or documented acquired QT prolongation Patients treated with other active drugs that prolong the QT interval such as: antiarrhythmics of classes IA and III, cisapride and terfenadine Patients with electrolyte disorders, particularly hypokalemia and hypomagnesemia Patients with clinically relevant bradycardia, arrhythmia or severe heart failure
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Heterotopic Ossification The patient is 18-80 years of age The patient has provided written informed consent The patient is scheduled for hip arthroscopy surgery for treatment of FAI The patient has an ASA of I, II, or III The patients understands the explanation of the protocol  The patient has history of a major GI bleeding event The patients has a history of renal impairment or creatinine > 1.5 The patient has taken NSAIDs within 48 hours of surgery or in the perioperative period The patient has a history of heterotopic ossification following surgery The patient has a hypersensitivity reaction to Naproxen The patient is undergoing a concomitant procedure in addition to treatment of FAI
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Cirrhosis Hepatic Encephalopathy Hyponatremia Cirrhosis diagnosed by liver biopsy or radiological evidence of nodular cirrhotic liver or varices on endoscopy or laboratory features (platelet count <150,000 with an AST/ALT ratio >1) History of HE controlled on lactulose and/or rifaximin Last HE episode >2 months prior to enrollment and <2 episodes within 6 months Mini-mental status exam score ≥25 Serum sodium <130mg/dl within the last 14 days and the day of enrollment Availability of a caregiver Able to undergo MR of the head  Uncontrolled HE manifested by MMSE <25 Alcohol abuse within 3 months Illicit drug use within 3 months Psychoactive drug use other than regularly scheduled anti-depressants or methadone Contraindication to MR examination (see attached MRI Safety Form) Placement of a transjugular intra-hepatic portosystemic shunt (TIPS) Creatinine Clearance less than 10 ml/min or undergoing hemodialysis HIV infection Use of azole medications Pregnancy
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Associated Diarrhea Male and female patients 18 years of age or older 2. Mild to moderate C.difficile associated diarrhea (CDAD) with a positive stool C.difficile toxin (by ELISA). 3. Either a first episode of CDAD or a first recurrence (patients with more than 1 recurrence are not eligible) 4. Greater than 3 watery or unformed bowel movements in the prior 24 hours 5. Females of child bearing potential having a negative pregnancy test and taking adequate birth control measures. 6. Patients should not consume alcohol at least 12 hours prior to dosing (i.e. in-house monitoring) and until 48 hours after the last dose of drug administration (until Day 14). 7. Able to comprehend and give informed consent for the study and able to adhere to study schedules and protocol requirements  Known prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives 2. Life expectancy ≤ 60 days 3. Sepsis, severe sepsis, or septic shock 4. Signs or symptoms of peritonitis, megacolon or ileus 5. History of ulcerative colitis or Crohn's disease 6. Oral or parenteral antibiotic therapy with metronidazole or vancomycin or other drugs effective in treating DCAD (e.g., bacitracin, fusidic acid) within the 1 week prior to enrollment 7. Recent history of significant drug or alcohol abuse within 1 year 8. Any findings on physical examination, medical history, 12-lead ECG or clinical laboratory tests which, in the judgment of the Principal Investigator, would patients from participating in the study 9. Patients with history of blood dyscrasias, porphyria and active non-infectious disease of the central nervous system 10. Patients with history of rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption 11. Pregnant or lactating female patients 12. Participation within 30 days before the start of this study in any experimental drug or device study, or currently participating in a study in which the administration of investigational drug or device within 60 days is anticipated 13. Unable to participate in the study for any reason in the opinion of the Principal Investigator
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 0.833-3.0,  Acute Diarrhea Acute Gastroenteritis All acute diarrhea  Severe malnourishment Severe dehydration Systemic infections
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Antibiotic Associated Diarrhea Clostridium Difficile Associated Diarrhea years of age or older admitted to SSH and prescribed antibiotics for an expected duration >3 days (may patients on antibiotics prior to admission)  History of chronic diarrhea illness (Irritable Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Celiac Disease, Chronic pancreatitis 2. Diarrhea at screening 3. Active Colitis of any etiology 4. History of colectomy 5. Regular consumption of probiotics within 72 hours 6. Unable to provide written consent 7. History of or active pancreatitis 8. Severe Sepsis or Septic Shock (sepsis with end organ failure e.g. renal failure, ARDS, MS changes and or meets by n ational guideline, and or requiring vasopressors) 9. Hypersensitivity to any ingredient in probiotic product 10. Severe Immunosuppression (ANC <1000, AIDS/CD4 count <200 cells, cancer on active chemothereapy, h/o of solid or bone marrow transplant) 12. Acute burn injuries